Related Experiment Videos
Fibrinolytic activity in malignant disease.
Journal of Clinical Pathology
|November 1, 1975
Summary
Patients with cancer show reduced resting fibrinolytic activity, especially with widespread disease. However, their overall fibrinolytic capacity remains comparable to healthy individuals, indicating a complex impact of malignancy on blood clot breakdown.
Area of Science:
- Biochemistry
- Oncology
- Hematology
Background:
- Fibrinolysis is crucial for dissolving blood clots.
- Malignant diseases can affect hemostasis and thrombosis.
- Understanding fibrinolytic function in cancer is vital for managing complications.
Purpose of the Study:
- To compare resting fibrinolytic activity and capacity in cancer patients versus controls.
- To investigate if malignant disease impacts the body's ability to break down clots.
Main Methods:
- Measured resting fibrinolytic activity in 31 cancer patients and 24 controls.
- Assessed fibrinolytic capacity in both groups.
- Compared results between patients with malignant disease and healthy subjects.
Main Results:
- Cancer patients exhibited significantly lower mean resting fibrinolytic activity.
- This reduction in activity was more pronounced in patients with disseminated malignant disease.
- No significant difference was observed in fibrinolytic capacity between cancer patients and controls.
Conclusions:
- Malignant disease is associated with impaired resting fibrinolytic activity.
- Disseminated cancer exacerbates the reduction in fibrinolytic activity.
- Overall fibrinolytic capacity is preserved in patients with malignant disease.